The Board of Trustees of the Leland Stanford Junior University
发明人:
Strober, Samuel,Meyer, Everett Hurteau,Umetsu, Dale T.
申请号：
AU2011250800
公开号：
AU2011250800A1
申请日:
2011.11.16
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
#$%^&*AU2011250800A120120119.pdf#####ABSTRACT The present invention is directed to molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function. Said molecules are administered to patients for treatment of conditions such as systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiments of the invention, the inhibitory agent is an anergizing glycolipid, for example galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.
